RBC Thinks Waters’ 2027 Growth Story Still Holds
RBC Capital Markets reduced its 2027 operating-margin expansion forecast for Waters Corp. to 200 basis points, citing lower margins from Becton Dickinson assets. Despite this, RBC maintained a $475 price target and outperform rating, noting 3% higher EPS estimates than consensus. The firm cited mixed demand trends, with strong microbiology but weaker research-related sales. Waters' stock last traded at $407.93.
How this was made
The 30-second read
Why it matters
The downgrade signals a shift in growth assumptions, which may lead to a re‑rating by other analysts.
Market read
Analyst margin revision could trigger short‑term price volatility for Waters.
What to watch
Potential pricing power in microbiology consumables could offset margin dilution.
Background
RBC adjusted its 2027 operating‑margin outlook for Waters after integrating lower‑margin Becton Dickinson assets.
Ticker impact
RBC lowered its 2027 margin expansion forecast for Waters, noting a 200‑basis‑point reduction but kept a $475 price target.
Potential short‑term downside as investors reassess valuation multiples.
Margin compression reduces growth narrative; price target remains unchanged, creating a valuation gap.
Market effects
Biotech consumables sector may see broader scrutiny of margin assumptions.
North American biotech equities could face modest pressure.
Limited to investors tracking Waters and similar life‑science suppliers.
Counterpoint
The unchanged $475 target suggests upside if margins stabilize faster than expected.
Key entities
- companyWaters Corporation
Life‑science consumables maker (NASDAQ:WAT).
- analystRBC Capital Markets
Equity research firm providing the revised forecast.
%252FWaters%252520Corporation%252520on%252520the%252520screen%252520of%252520an%252520exchange_By%252520maurice%252520norbert.jpeg&w=3840&q=75)
